Melanie Machiels

Radiation Oncologist @ Iridium Network Antwerp | Associate Professor @ University of Antwerp | #breastcancer #gynaecologicalcancer #brachytherapy

[Melanie Machiels @mchiels]

Congratulations to the whole team! Proud to have contributed as co-author to this new publication from the International Immuno-Oncology Biomarker Working Group (@TILsWorkGroup ), out now in @LancetOncology.

https://t.co/imuDBYbsup

[MediMix @Medi_Mix]

🚨Highlights from #SABCS2024! Prof Dr @mchiels explores breakthroughs from the Rapid Fire Session 2:
- Axillary management: Alliance 11-202 findings
- Micrometastases & DFS: German Breast Group analysis
- Faster radiotherapy boosts: ULTIMATE trial outcomes
- TILs in ER-negative patients: Prognostic insights
- Managing chemotherapy nausea: Olanzapine's efficacy

[Melanie Machiels @mchiels]

Very honoured to present the interim-analysis of our ULTIMO trial at #SABCS24

[Alizée Camps - - Maléa @acampsmalea]

Rapid Fire 2 #SABC24

➡️ Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients.

One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO) ☢️

@OncoAlert #OncoAlertAF

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌Does Postmastectomy Radiotherapy in 'Intermediate-Risk' Breast Cancer Impact Overall Survival?
👉🏻10-Year Results of the BIG 2-04 MRC SUPREMO Randomized Trial: On Behalf of the SUPREMO Trial Investigators by Prof Ian Kunkler
#SABCS24 #day3 @OncoAlert #OncoAlertAF #GeneralSession2

[Melanie Machiels @mchiels]

The interim-analysis of the groundbreaking EUROPA trial demonstrates what we all have been thinking:
⁃Much less AE’s in the RT arm
⁃Better HRQoL preservation in the RT arm

Time for a paradigm shift! Congratulations @Icro_Meattini

#SABCS24

[Piet Ost @piet_ost]

Thanks to @komop_tgkanker and all the people supporting it, @gzaziekenhuizen and the Iridium Network will be able to conduct 2 new trials: PRADA (@mchiels) and OligoRare (me and @Mat_Guc with @EORTC), trying to improve outcomes for cancer patients!

[Breast & Lung Cancer Updates @ VuMedi @Sameh_VuMedi]

Check out Dr. Paolo Tarantino @PTarantinoMD @DFCI_BreastOnc discussing top 5 takeaways from #SABCS23 including KATHERINE & INAVO120

#bcsm #HER2 #TNBC #BreastCancer
full📽️on #VuMedi
👇
https://t.co/pg13y8v35Z

[Melanie Machiels @mchiels]

Proficiat @joostverhoeff!

[Ben Slotman @bslotman]

Succession planning is key. Very happy that, after leading the #radonc department at @amsterdamumc for almost 30 years, @joostverhoeff has taken over. I have peace of mind and time for other tasks!

[Melanie Machiels @mchiels]

Elective node irradiation including IMN for all high-risk #breastcancer patients from now on!

[Matthias Guckenberger @Mat_Guc]

Virtual Grand Rounds in Radiation Oncology

January 10th 17:00 - 17:30 CET

Prof. Carolyn Taylor:
Effect of regional lymph node radiotherapy. An EBCTCG meta-analysis of 14,324 women in 16 trials

Link to Zoom Meeting 👇
https://t.co/VMPm8mpHbj

[Matteo Lambertini, MD PhD @matteolambe]

Presented at #ESMO23 data from the #Keynote756 trial showing an increased pCR rate with the addition of #pembrolizumab to neoadjuvant chemotherapy in patients with high-risk hormone receptor-positive HER2-negative #BreastCancer

@myESMO @OncoAlert #bcsm

[Melanie Machiels @mchiels]

@joostverhoeff @amsterdamumc @bslotman Proficiat Joost!! Welverdiend!!

[Melanie Machiels @mchiels]

The past is a place to learn from, not to live in 🧐 Onwards with #genomicclassifiers for individualization of #Radiotherapy

[Shane Stecklein, MD, PhD @shanestecklein]

LUMINA: 2.3% 5-yr IBTR in women ≥55 w/ G1-2 pT1N0 luminal A (ER≥1%, PR≥20%, HER2-neg, Ki-67≤13.25%) #breastcancer s/p lump w/o #radiotherapy. Path forward: #Genomic classifiers of individual RT benefit, not omitting based on clinicopathologic features. https://t.co/v4Pyqoi3oR

[Shane Stecklein, MD, PhD @shanestecklein]

Happy to have contributed to this excellent review led by @mchiels focused on using #TILs and genomic #biomarkers to individualize #radiotherapy in #breastcancer. https://t.co/qNQkWtX0pT

[Melanie Machiels @mchiels]

Has the time come to individualize #radiotherapy using #TILs and genomic #biomarkers?

[Shane Stecklein, MD, PhD @shanestecklein]

Happy to have contributed to this excellent review led by @mchiels focused on using #TILs and genomic #biomarkers to individualize #radiotherapy in #breastcancer. https://t.co/qNQkWtX0pT

[Sushil @Sushilberiwal]

lack of RNI benefit in low genomic score disease irrespective of whether they got chemo or not #bcsm ⁦@AndrewKellerMD⁩ ⁦@CShahMD⁩ ⁦@ErinGillespieMD⁩ ⁦@Icro_Meattini⁩ #bcsm https://t.co/21xgXHlMtB

[Icro Meattini @Icro_Meattini]

Magnificent overview on when and how to use a nodal boost performed by @IBCradiation Wendy Woodward #ESTRO23
@OncoAlert #OncoAlert #radonc #breastcancer

[Melanie Machiels @mchiels]

*thank you // note to self: do not tweet when sleep deprivated

[Melanie Machiels @mchiels]

Thank for discussing preoperative #breastcancer #radiotherapy with me @HospitalULaPaz. The future is now (and female) 🔥

[Icro Meattini @Icro_Meattini]

PRIME II trial long-term results on @NEJM - Outstanding results reinforcing the positive impact of postoperative RT on local recurrence regardless of age (9.5% vs 0.9% 10 years).
I suggest reading this brilliant commentary by @jenniferbellon2 and Alice Ho https://t.co/vE7XL2qlzr

[Melanie Machiels @mchiels]

@VingerhoedW The best! 🔥